Skip to main content
. 2020 Sep 8;34:116. doi: 10.34171/mjiri.34.116

Table 1. Comparison of characteristics of registered protocols in ClinicalTrials.gov a and IRCT .

Characteristics ClinicalTrials.gov ( N=119,840) IRCT ( N=1751) P-value
Randomization <0.001 b
Non-randomized 41266 (34.4%) 44 (2.5%)
Randomized 74313 (62.0%) 1541 (88%)
N/A 0 166 (9.5%)
Allocation missing 4261 (3.6%) 0
Blinding <0.001 b
Open label 64222 (53.6%) 578 (33%)
Single blind 6383 (5.3%) 322 (18.4%)
Double blind 45094 (37.6%) 753 (43%)
Triple blind 0 98 (5.6%)
Masking missing 4141 (3.5%) 0
Study centers <0.001 b
Multi-center 44775 (37.4%) 212 (12.1%)
Single-center 75065 (62.6%) 1539 (87.9%)
Median sample size (IQR) f 60 (26-157) 66 (45-100) <0.001 b
<100 74780 (62.4%) 1247 (71.2%)
≥100 45059 (37.6%) 485 (27.7%)
Study duration (days) Median (IQR) f 701.0 (335-1,218) 177.5 (90-364) -
Funding: f <0.001 b
Industry 62556 (52.2%) 37 (2.1%)
Public 13541 (11.3%) 1529 (87.3%)
Others 43741 (36.5%) 185 (10.6%)
Purpose <0.001 b
Treatment 94074 (78.5%) 1022 (58.4%)
Prevention 10306 (8.6%) 360 (20.6%)
Number of study groups <0.001 b
Single group 42902 (35.8%) 146 (8.3%)
Controlled group 76937 (64.2%) 1605 (91.7%)
Phase II-IV trials published in scientific journal 8338 (29.9%) d 160 (47.7%) e -
Scientometric measures
CiteScore 3.01 (2.28-4.46) 1.44 (0.88-2.22) <0.001 c
SNIP 1.32 (0.98-2) 0.83 (0.59-1.01) <0.001c
SJR 1.67 (1.1-3.23) 0.58 (0.34-0.91) <0.001c

aData is reported by Magdalena Zwierzyna et alb P-values are calculated using chi squared test; cP-values are calculated using Mann-Whitney U test; d Of 27835 phase II-IV registered protocols in ClinicalTrials.gov; e Of 335 phase II-IV of registered protocols in IRCT; fmissing values are less than 1.5% in IRCT